{"ticker": {"uuid": "b9292ba4-f8ac-4a1d-8792-aa3034145d5e", "symbol": "PLYX", "name": "Polaryx Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Polaryx Therapeutics Announces Chief Medical Officer Resignation", "summary": "Polaryx Therapeutics, Inc. announced the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, effective July 19, 2026. The company stated that this departure is not expected to impact clinical timelines, regulatory plans, or development strategy, with existing ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3414170/polaryx-therapeutics-announces-chief-medical-officer-resignation/", "source_name": "The Globe and Mail", "published_at": "2026-07-22T21:12:28", "published_display": "22 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis", "summary": "This article provides an overview of Polaryx Therapeutics, Inc. (NASDAQ: PLYX) stock, including its current price, daily range, and a snapshot of its fundamental metrics such as previous close, market capitalization, and trading volume. It also offers sections for financial chart", "url": "https://kalkine.com.au/company/nasdaq-plyx/", "source_name": "Kalkine", "published_at": "2026-07-21T15:09:28", "published_display": "21 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026", "summary": "Polaryx Therapeutics, Inc. announced the resignation of Lisa Bollinger, MD, as Chief Medical Officer, effective July 19, 2026. The company does not expect her departure to impact its clinical timelines, regulatory plans, or development strategy. A search for a successor has begun", "url": "https://www.marketscreener.com/news/polaryx-therapeutics-inc-announces-resignation-of-lisa-bollinger-from-chief-medical-officer-effec-ce7f51d8d189f721", "source_name": "www.marketscreener.com", "published_at": "2026-07-21T04:31:00", "published_display": "21 Jul 2026 04:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline", "summary": "Polaryx Therapeutics (PLYX) has announced that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. The record date for stockholders eligible to vote is July 27, 2026. The deadline for stockholder proposals and director nominations to be included ", "url": "https://www.stocktitan.net/sec-filings/PLYX/8-k-polaryx-therapeutics-inc-reports-material-event-3f9a827f591f.html", "source_name": "Stock Titan", "published_at": "2026-07-17T12:10:56", "published_display": "17 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual event", "summary": "Polaryx Therapeutics has announced that its 2026 annual stockholders meeting will be held virtually on September 10, 2026. Shareholders recorded as of July 27, 2026, will be eligible to vote. The company plans to release further details regarding the matters to be voted upon in a", "url": "https://www.bitget.com/amp/news/detail/12560605514569", "source_name": "Bitget", "published_at": "2026-07-17T12:02:00", "published_display": "17 Jul 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What is HC Wainwright's Forecast for PLYX Q2 Earnings?", "summary": "HC Wainwright forecasts Polaryx Therapeutics (NASDAQ: PLYX) will report Q2 2026 EPS of ($0.05) and has reiterated a Buy rating with a $7.00 price target. The firm's longer-term estimates indicate continued losses through FY2027, with quarterly projections remaining consistent aro", "url": "https://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-plyx-q2-earnings-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T05:41:44", "published_display": "13 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to \"Sell\"", "summary": "Polaryx Therapeutics (NASDAQ:PLYX) has been downgraded from a \"hold\" to a \"sell\" rating by Wall Street Zen, adding a bearish sentiment to existing analyst coverage. This contrasts with a \"buy\" rating and $7.00 price target from HC Wainwright, leading to an overall \"Hold\" consensu", "url": "https://www.marketbeat.com/instant-alerts/polaryx-therapeutics-nasdaqplyx-downgraded-by-wall-street-zen-to-sell-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T17:40:04", "published_display": "12 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investment firm H.C. Wainwright announced today the launch of initial coverage research on biopharmaceutical company Polaryx Therapeutics Inc.", "summary": "Investment firm H.C. Wainwright has initiated coverage on biopharmaceutical company Polaryx Therapeutics Inc., assigning a \"Buy\" rating and a target price of $7 for its stock. This move suggests optimism among analysts regarding the company's future development and potential valu", "url": "https://www.bitget.com/amp/news/detail/12560605497568", "source_name": "Bitget", "published_at": "2026-07-11T22:41:45", "published_display": "11 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has initiated coverage on Polaryx Therapeutics with a \"Buy\" rating. This indicates an optimistic outlook from the analytical firm regarding the company's future performance or potential. Investors may see this as a positive signal for Polaryx Therapeutics.", "url": "https://www.moomoo.com/news/post/72709884/polaryx-therapeutics-initiated-at-buy-by-hc-wainwright-co?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T08:09:47", "published_display": "10 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating", "summary": "H.C. Wainwright has initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a price target of $7.00, representing a significant upside. The firm highlighted PLX-200, a repurposed oral drug targeting fatal pediatric central nervous system lysosomal storage d", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-polaryx-therapeutics-stock-with-buy-rating-93CH-4783777", "source_name": "Investing.com", "published_at": "2026-07-09T11:40:08", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com", "summary": "H.C. Wainwright initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a $7.00 price target, representing a potential 175% upside. The firm highlighted Polaryx's lead drug candidate, PLX-200, which targets fatal pediatric central nervous system lysosomal s", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-initiates-polaryx-therapeutics-stock-with-buy-rating-93CH-2592902", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T11:17:44", "published_display": "09 Jul 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Polaryx Therapeutics, Inc. \u2013 FWB:1V8", "summary": "The article provides a title focusing on the free cash flow per share of Polaryx Therapeutics, Inc. (FWB:1V8) on the Frankfurt Stock Exchange. The content primarily consists of website navigation, disclaimers, and links to various financial tools and community features rather tha", "url": "https://www.tradingview.com/symbols/FWB-1V8/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-03T20:17:44", "published_display": "03 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Operating cash flow per share of Polaryx Therapeutics, Inc. \u2013 FWB:1V8", "summary": "The article focuses on the operating cash flow per share of Polaryx Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the symbol 1V8. It appears to be a financial data page from TradingView, indicating the market is closed with no current trades. The content primar", "url": "https://www.tradingview.com/symbols/FWB-1V8/financials-statistics-and-ratios/operating-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-03T16:40:26", "published_display": "03 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "The article focuses on the \"Enterprise value to revenue forward\" metric for Polaryx Therapeutics, Inc., traded on Nasdaq under the symbol PLYX. It appears to be a financial data snippet from a larger platform, indicating a specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:11:11", "published_display": "28 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "This article displays the Enterprise Value to EBIT forward for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) through a TradingView snapshot. The market is currently closed for this stock, and no trades have been made. The information is presented within a financial data analysis cont", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:11", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "The article discusses the forward price-to-sales ratio for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) on TradingView. It provides a brief financial overview of the company, indicating the market is closed with no trades. The article is a snippet related to financial data availabil", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:38", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX)", "summary": "Polaryx Therapeutics, Inc. (NASDAQ:PLYX) is currently trading at $2.31, experiencing a recent decline. Analysts have a maximum and minimum price target of $10.00 for PLYX. The company has a market capitalization of $109.36 million and is scheduled to release its next earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:58", "published_display": "26 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Polaryx Therapeutics Ord Shs (PLYX) has received a \"Buy\" rating from analysts, with one analyst predicting a significant upside of +321.94% for its target price. The article provides an overview of the company's earnings forecast and analyst ratings, noting that relevant financia", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plyx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:39", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History", "summary": "This page provides a comprehensive overview of Polaryx Therapeutics Inc. (PLYX) stock, including its current price, historical data, recent news, and key financial statistics. It details the company's focus on developing therapies for rare pediatric lysosomal storage disorders an", "url": "https://www.benzinga.com/quote/PLYX", "source_name": "Benzinga", "published_at": "2026-06-13T21:40:36", "published_display": "13 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc Short Interest", "summary": "This article provides detailed short interest and financial data for Polaryx Therapeutics Inc (PLYX). It includes current stock performance metrics, key financial indicators like market cap, sales, and EPS, alongside insider ownership and institutional transactions, and short int", "url": "https://finviz.com/stock?t=PLYX&ty=si", "source_name": "Finviz", "published_at": "2026-06-09T07:41:51", "published_display": "09 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial", "summary": "Polaryx Therapeutics has closed a $10 million private placement equity financing round. This funding is intended to support the launch of its SOTERIA Phase 2 basket trial. The trial will evaluate PLX-200, an oral therapeutic, for its efficacy in treating multiple rare indications", "url": "https://www.moomoo.com/news/post/70709809/polaryx-therapeutics-announces-closing-of-10-million-private-placement-equity", "source_name": "Moomoo", "published_at": "2026-05-30T06:08:41", "published_display": "30 May 2026 06:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MStone affiliate of Polaryx Therapeutics (PLYX) buys 88K common shares", "summary": "MStone Partners Healthcare Limited, an affiliate of Polaryx Therapeutics (PLYX) and founded by Polaryx CEO Alex Keun Mo Yang, purchased 88,453 shares of Polaryx common stock in a private placement. This transaction, which occurred on May 27, 2026, generated $360,000 in gross proc", "url": "https://www.stocktitan.net/sec-filings/PLYX/form-4-polaryx-therapeutics-inc-insider-trading-activity-6d42103676f4.html", "source_name": "Stock Titan", "published_at": "2026-05-29T16:40:53", "published_display": "29 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics closes $10 million PIPE financing By Investing.com", "summary": "Polaryx Therapeutics has successfully closed a $10 million Private Investment in Public Equity (PIPE) financing, selling over 2.5 million shares at approximately $4.00 per share. The biotechnology company plans to use these proceeds, along with existing cash, to fund the initiati", "url": "https://ng.investing.com/news/stock-market-news/polaryx-therapeutics-closes-10-million-pipe-financing-93CH-2533240", "source_name": "Investing.com Nigeria", "published_at": "2026-05-29T02:10:23", "published_display": "29 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc. stock news, filings & ratings", "summary": "Polaryx Therapeutics (PLYX) stock is currently priced at $3.28, up 6.84%. Recent notable events include the CEO's purchase of $360,004 worth of shares, the closing of a $10 million private placement equity financing, and multiple U.S. FDA Fast Track Designations for its lead cand", "url": "https://quantisnow.com/company/PLYX", "source_name": "Quantisnow", "published_at": "2026-05-29T02:10:23", "published_display": "29 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics CEO\u2019s Mstone buys $360,003 in PLYX stock", "summary": "Mstone Partners Healthcare Ltd, an entity where Polaryx Therapeutics CEO Alex Keun Mo Yang serves as founder and CEO, purchased 88,453 shares of Polaryx Therapeutics (PLYX) common stock for $360,003 in a private placement. This transaction occurred on May 27, 2026, at $4.07 per s", "url": "https://m.investing.com/news/insider-trading-news/polaryx-therapeutics-ceos-mstone-buys-360003-in-plyx-stock-93CH-4715816?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-29T00:09:42", "published_display": "29 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx (PLYX) secures $10M PIPE to fund SOTERIA trial and extend runway to Q2 2027", "summary": "Polaryx Therapeutics, Inc. (PLYX) has announced a $10 million private placement, selling 2,502,696 common shares at a weighted average price of $4.00 per share. These proceeds, combined with existing cash, will fund the initiation of the Phase 2 SOTERIA basket trial for PLX-200 a", "url": "https://www.stocktitan.net/sec-filings/PLYX/8-k-polaryx-therapeutics-inc-reports-material-event-405afb37bc92.html", "source_name": "Stock Titan", "published_at": "2026-05-28T20:08:47", "published_display": "28 May 2026 20:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx raises $10M to launch 2026 PLX-200 trial in rare pediatric lysosomal diseases", "summary": "Polaryx Therapeutics has successfully closed a $10 million private investment in public equity (PIPE) financing, issuing 2,502,696 common shares at approximately $4.00 each. These funds are designated to initiate the Phase 2 SOTERIA basket trial of PLX-200, targeting multiple lys", "url": "https://www.stocktitan.net/news/PLYX/polaryx-therapeutics-announces-closing-of-10-million-private-fydzt434pso4.html", "source_name": "Stock Titan", "published_at": "2026-05-28T12:39:51", "published_display": "28 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Polaryx Therapeutics Stock Is Surging On Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPQTc0TS1EYmZHMkcxTVZLQWsybGxqYUI3blU4c0t1Nnpqb0N1OFJNNVFPaTBVc2FNWnhkWlgtZDhsVWI3UTF0RG1LckJGWnpKM0VZcVlDSGMtdWItdnZOZ0tGX25hb0U3S2ZxcVU1bUJ3TENLbGNSUEdxZ2lmVFNCanlUanNPeU01STlFazRfOXBlUmN5UmJIZUN6TzdpcXJ4MUJsdWRTenlzeGZScFJfUkRLem8?oc=5", "source_name": "Benzinga", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc Stock Price and Quote", "summary": "Polaryx Therapeutics Inc (PLYX) stock experienced a significant ~28% drop, driven by concerns over cash runway and going concern doubts. The company recently received multiple FDA Fast Track Designations for its SOTERIA basket trial and is actively participating in healthcare con", "url": "https://finviz.com/stock?t=PLYX", "source_name": "Finviz", "published_at": "2026-05-26T20:09:23", "published_display": "26 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$PLYX stock is down 32% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQcXJVV2Q1MlByMmJDNWlPS00yTVBzV1BDRkJVczBrcHZsOHdaLTVoSzJzSXFocXRTN1dpdUlQOWNLNGRhZ2dZQWJ5WXpFNXBLQW1nRkd0aFRmdlBuZTJscVNVMjhiNm96clY1aE9KQkRhNjZXeVoxNl9KdnlJSElKaUk0UnVQRHRYaUxiNjlqdVdvRk1KcFhsZWs0UEFrcWtjcHhZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies", "summary": "Polaryx Therapeutics, Inc. reported a Q1 2026 net loss of $2.5 million and an accumulated deficit of $102.2 million, with only $250,000 in cash. The company faces significant financial risks, including a \"going concern\" warning due to recurring losses and limited cash, necessitat", "url": "https://www.minichart.com.sg/2026/05/15/polaryx-therapeutics-inc-q1-2026-financial-results-and-pipeline-update-progress-in-rare-pediatric-lysosomal-storage-disorder-therapies/", "source_name": "Minichart", "published_at": "2026-05-15T21:40:57", "published_display": "15 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Polaryx Therapeutics Receives GHP Magazine\u2019s Healthcare & Pharmaceuticals Awards", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polaryx-therapeutics-receives-ghp-magazine-131500539.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T13:15:00+00:00", "published_display": "14 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PLYX Stock Price and Chart \u2014 NASDAQ:PLYX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5yb04xdnV1NWxCcUt5OFJ2Q1NwSnc0NFVIOFNxQW1oZU16a2FqQUxOU2ZtMkFtbGY2ajhLYmNSM0lRcDdGQm56eVV3RUhBbXF1X0pRcUNJSUdpcjVY?oc=5", "source_name": "TradingView", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Stock Surges With New Phase Trial Decision\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNVGxvMlV0OWUzSzMxQk91QmtvWUZEbXJqQXVQZ3NNUEFjNmxXd2xHeEpkVkhudFBtaEhwSWdibWRha3JSMGJXR2RXUUU4bHUxTXVmajFtRGlIc29VT2daRThhRjh3M215RG5tSFV3YTRybmY0N3lpNkROTXY2RmUweA?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNTTA3aWNkN0VsX3pQS2c5NWQ3WlBTak1zaHlPZTkyV08xLUtxYUhSQ1dzdmVZWHR6RFVzN2paSkl4ZDZYeWZkRHFLSEtmUWdBVUxJdmZDQUlGeGU1OUlLNl8yNkVNbTdIV2diVXl0Vk42OF9iSGpOU19BSGg0RDdOSzl4bkJGM0NNbmtnVVAwWXlFVC0yUmV0MmJ0OVVZV08wczFXYThqZG1lbWdNUUh4amFreERBeDBFR29kMkN2dlNjYTNOaUROQVAzZFNIUUwwTEJ6TVg0WS03azA5cFNUVmdnaWlIb3F0X3hHeGdxTmdsOEk?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNnRBTFd6S0llSFhnNVZ5VWlUSHRFZE04RlVaS3FyYmEzejFrX3FxSEZTUUgxLWRHaTNiYVFkaU40V0UwbDVueFdwakoxVWg0NGhhMUgxTGtkSG9qTy1qUmhrSzQtZw?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-21T05:31:39+00:00", "published_display": "21 Feb 2026 05:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYOWx4Tkw2N3pIbWdZTFR3d0ZQb3NNT1RVSDFuRDBxZU9PNzFBTEgwbnFOejl5X0R1NF9sc2FhSm9jYWRpNk1peEtfd1FUa240czJsaVBNRmdHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-21T02:28:09+00:00", "published_display": "21 Feb 2026 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9MWl83QmxVZllZei1OaVFyMWtVNUNBcDdid081TWVjdy1KVnkxaGpaTTBzcmI0Vm9yeUlDaW5veW5VTUYzTU1icHp5R3dEcjY2?oc=5", "source_name": "CNN", "published_at": "2026-02-01T05:58:29+00:00", "published_display": "01 Feb 2026 05:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Polaryx Therapeutics Announces Chief Medical Officer Resignation", "summary": "Polaryx Therapeutics, Inc. announced the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, effective July 19, 2026. The company stated that this departure is not expected to impact clinical timelines, regulatory plans, or development strategy, with existing ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3414170/polaryx-therapeutics-announces-chief-medical-officer-resignation/", "source_name": "The Globe and Mail", "published_at": "2026-07-22T21:12:28", "published_display": "22 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis", "summary": "This article provides an overview of Polaryx Therapeutics, Inc. (NASDAQ: PLYX) stock, including its current price, daily range, and a snapshot of its fundamental metrics such as previous close, market capitalization, and trading volume. It also offers sections for financial chart", "url": "https://kalkine.com.au/company/nasdaq-plyx/", "source_name": "Kalkine", "published_at": "2026-07-21T15:09:28", "published_display": "21 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026", "summary": "Polaryx Therapeutics, Inc. announced the resignation of Lisa Bollinger, MD, as Chief Medical Officer, effective July 19, 2026. The company does not expect her departure to impact its clinical timelines, regulatory plans, or development strategy. A search for a successor has begun", "url": "https://www.marketscreener.com/news/polaryx-therapeutics-inc-announces-resignation-of-lisa-bollinger-from-chief-medical-officer-effec-ce7f51d8d189f721", "source_name": "www.marketscreener.com", "published_at": "2026-07-21T04:31:00", "published_display": "21 Jul 2026 04:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline", "summary": "Polaryx Therapeutics (PLYX) has announced that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. The record date for stockholders eligible to vote is July 27, 2026. The deadline for stockholder proposals and director nominations to be included ", "url": "https://www.stocktitan.net/sec-filings/PLYX/8-k-polaryx-therapeutics-inc-reports-material-event-3f9a827f591f.html", "source_name": "Stock Titan", "published_at": "2026-07-17T12:10:56", "published_display": "17 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual event", "summary": "Polaryx Therapeutics has announced that its 2026 annual stockholders meeting will be held virtually on September 10, 2026. Shareholders recorded as of July 27, 2026, will be eligible to vote. The company plans to release further details regarding the matters to be voted upon in a", "url": "https://www.bitget.com/amp/news/detail/12560605514569", "source_name": "Bitget", "published_at": "2026-07-17T12:02:00", "published_display": "17 Jul 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is HC Wainwright's Forecast for PLYX Q2 Earnings?", "summary": "HC Wainwright forecasts Polaryx Therapeutics (NASDAQ: PLYX) will report Q2 2026 EPS of ($0.05) and has reiterated a Buy rating with a $7.00 price target. The firm's longer-term estimates indicate continued losses through FY2027, with quarterly projections remaining consistent aro", "url": "https://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-plyx-q2-earnings-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T05:41:44", "published_display": "13 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to \"Sell\"", "summary": "Polaryx Therapeutics (NASDAQ:PLYX) has been downgraded from a \"hold\" to a \"sell\" rating by Wall Street Zen, adding a bearish sentiment to existing analyst coverage. This contrasts with a \"buy\" rating and $7.00 price target from HC Wainwright, leading to an overall \"Hold\" consensu", "url": "https://www.marketbeat.com/instant-alerts/polaryx-therapeutics-nasdaqplyx-downgraded-by-wall-street-zen-to-sell-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T17:40:04", "published_display": "12 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investment firm H.C. Wainwright announced today the launch of initial coverage research on biopharmaceutical company Polaryx Therapeutics Inc.", "summary": "Investment firm H.C. Wainwright has initiated coverage on biopharmaceutical company Polaryx Therapeutics Inc., assigning a \"Buy\" rating and a target price of $7 for its stock. This move suggests optimism among analysts regarding the company's future development and potential valu", "url": "https://www.bitget.com/amp/news/detail/12560605497568", "source_name": "Bitget", "published_at": "2026-07-11T22:41:45", "published_display": "11 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has initiated coverage on Polaryx Therapeutics with a \"Buy\" rating. This indicates an optimistic outlook from the analytical firm regarding the company's future performance or potential. Investors may see this as a positive signal for Polaryx Therapeutics.", "url": "https://www.moomoo.com/news/post/72709884/polaryx-therapeutics-initiated-at-buy-by-hc-wainwright-co?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T08:09:47", "published_display": "10 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating", "summary": "H.C. Wainwright has initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a price target of $7.00, representing a significant upside. The firm highlighted PLX-200, a repurposed oral drug targeting fatal pediatric central nervous system lysosomal storage d", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-initiates-polaryx-therapeutics-stock-with-buy-rating-93CH-4783777", "source_name": "Investing.com", "published_at": "2026-07-09T11:40:08", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com", "summary": "H.C. Wainwright initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and a $7.00 price target, representing a potential 175% upside. The firm highlighted Polaryx's lead drug candidate, PLX-200, which targets fatal pediatric central nervous system lysosomal s", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-initiates-polaryx-therapeutics-stock-with-buy-rating-93CH-2592902", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T11:17:44", "published_display": "09 Jul 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Polaryx Therapeutics, Inc. \u2013 FWB:1V8", "summary": "The article provides a title focusing on the free cash flow per share of Polaryx Therapeutics, Inc. (FWB:1V8) on the Frankfurt Stock Exchange. The content primarily consists of website navigation, disclaimers, and links to various financial tools and community features rather tha", "url": "https://www.tradingview.com/symbols/FWB-1V8/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-03T20:17:44", "published_display": "03 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Operating cash flow per share of Polaryx Therapeutics, Inc. \u2013 FWB:1V8", "summary": "The article focuses on the operating cash flow per share of Polaryx Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the symbol 1V8. It appears to be a financial data page from TradingView, indicating the market is closed with no current trades. The content primar", "url": "https://www.tradingview.com/symbols/FWB-1V8/financials-statistics-and-ratios/operating-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-03T16:40:26", "published_display": "03 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "The article focuses on the \"Enterprise value to revenue forward\" metric for Polaryx Therapeutics, Inc., traded on Nasdaq under the symbol PLYX. It appears to be a financial data snippet from a larger platform, indicating a specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:11:11", "published_display": "28 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "This article displays the Enterprise Value to EBIT forward for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) through a TradingView snapshot. The market is currently closed for this stock, and no trades have been made. The information is presented within a financial data analysis cont", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:11", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Polaryx Therapeutics, Inc. \u2013 NASDAQ:PLYX", "summary": "The article discusses the forward price-to-sales ratio for Polaryx Therapeutics, Inc. (NASDAQ: PLYX) on TradingView. It provides a brief financial overview of the company, indicating the market is closed with no trades. The article is a snippet related to financial data availabil", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:38", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX)", "summary": "Polaryx Therapeutics, Inc. (NASDAQ:PLYX) is currently trading at $2.31, experiencing a recent decline. Analysts have a maximum and minimum price target of $10.00 for PLYX. The company has a market capitalization of $109.36 million and is scheduled to release its next earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-PLYX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:58", "published_display": "26 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Polaryx Therapeutics Ord Shs (PLYX) has received a \"Buy\" rating from analysts, with one analyst predicting a significant upside of +321.94% for its target price. The article provides an overview of the company's earnings forecast and analyst ratings, noting that relevant financia", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plyx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:39:39", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History", "summary": "This page provides a comprehensive overview of Polaryx Therapeutics Inc. (PLYX) stock, including its current price, historical data, recent news, and key financial statistics. It details the company's focus on developing therapies for rare pediatric lysosomal storage disorders an", "url": "https://www.benzinga.com/quote/PLYX", "source_name": "Benzinga", "published_at": "2026-06-13T21:40:36", "published_display": "13 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc Short Interest", "summary": "This article provides detailed short interest and financial data for Polaryx Therapeutics Inc (PLYX). It includes current stock performance metrics, key financial indicators like market cap, sales, and EPS, alongside insider ownership and institutional transactions, and short int", "url": "https://finviz.com/stock?t=PLYX&ty=si", "source_name": "Finviz", "published_at": "2026-06-09T07:41:51", "published_display": "09 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial", "summary": "Polaryx Therapeutics has closed a $10 million private placement equity financing round. This funding is intended to support the launch of its SOTERIA Phase 2 basket trial. The trial will evaluate PLX-200, an oral therapeutic, for its efficacy in treating multiple rare indications", "url": "https://www.moomoo.com/news/post/70709809/polaryx-therapeutics-announces-closing-of-10-million-private-placement-equity", "source_name": "Moomoo", "published_at": "2026-05-30T06:08:41", "published_display": "30 May 2026 06:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MStone affiliate of Polaryx Therapeutics (PLYX) buys 88K common shares", "summary": "MStone Partners Healthcare Limited, an affiliate of Polaryx Therapeutics (PLYX) and founded by Polaryx CEO Alex Keun Mo Yang, purchased 88,453 shares of Polaryx common stock in a private placement. This transaction, which occurred on May 27, 2026, generated $360,000 in gross proc", "url": "https://www.stocktitan.net/sec-filings/PLYX/form-4-polaryx-therapeutics-inc-insider-trading-activity-6d42103676f4.html", "source_name": "Stock Titan", "published_at": "2026-05-29T16:40:53", "published_display": "29 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics closes $10 million PIPE financing By Investing.com", "summary": "Polaryx Therapeutics has successfully closed a $10 million Private Investment in Public Equity (PIPE) financing, selling over 2.5 million shares at approximately $4.00 per share. The biotechnology company plans to use these proceeds, along with existing cash, to fund the initiati", "url": "https://ng.investing.com/news/stock-market-news/polaryx-therapeutics-closes-10-million-pipe-financing-93CH-2533240", "source_name": "Investing.com Nigeria", "published_at": "2026-05-29T02:10:23", "published_display": "29 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc. stock news, filings & ratings", "summary": "Polaryx Therapeutics (PLYX) stock is currently priced at $3.28, up 6.84%. Recent notable events include the CEO's purchase of $360,004 worth of shares, the closing of a $10 million private placement equity financing, and multiple U.S. FDA Fast Track Designations for its lead cand", "url": "https://quantisnow.com/company/PLYX", "source_name": "Quantisnow", "published_at": "2026-05-29T02:10:23", "published_display": "29 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics CEO\u2019s Mstone buys $360,003 in PLYX stock", "summary": "Mstone Partners Healthcare Ltd, an entity where Polaryx Therapeutics CEO Alex Keun Mo Yang serves as founder and CEO, purchased 88,453 shares of Polaryx Therapeutics (PLYX) common stock for $360,003 in a private placement. This transaction occurred on May 27, 2026, at $4.07 per s", "url": "https://m.investing.com/news/insider-trading-news/polaryx-therapeutics-ceos-mstone-buys-360003-in-plyx-stock-93CH-4715816?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-29T00:09:42", "published_display": "29 May 2026 00:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx (PLYX) secures $10M PIPE to fund SOTERIA trial and extend runway to Q2 2027", "summary": "Polaryx Therapeutics, Inc. (PLYX) has announced a $10 million private placement, selling 2,502,696 common shares at a weighted average price of $4.00 per share. These proceeds, combined with existing cash, will fund the initiation of the Phase 2 SOTERIA basket trial for PLX-200 a", "url": "https://www.stocktitan.net/sec-filings/PLYX/8-k-polaryx-therapeutics-inc-reports-material-event-405afb37bc92.html", "source_name": "Stock Titan", "published_at": "2026-05-28T20:08:47", "published_display": "28 May 2026 20:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx raises $10M to launch 2026 PLX-200 trial in rare pediatric lysosomal diseases", "summary": "Polaryx Therapeutics has successfully closed a $10 million private investment in public equity (PIPE) financing, issuing 2,502,696 common shares at approximately $4.00 each. These funds are designated to initiate the Phase 2 SOTERIA basket trial of PLX-200, targeting multiple lys", "url": "https://www.stocktitan.net/news/PLYX/polaryx-therapeutics-announces-closing-of-10-million-private-fydzt434pso4.html", "source_name": "Stock Titan", "published_at": "2026-05-28T12:39:51", "published_display": "28 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Polaryx Therapeutics Stock Is Surging On Thursday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPQTc0TS1EYmZHMkcxTVZLQWsybGxqYUI3blU4c0t1Nnpqb0N1OFJNNVFPaTBVc2FNWnhkWlgtZDhsVWI3UTF0RG1LckJGWnpKM0VZcVlDSGMtdWItdnZOZ0tGX25hb0U3S2ZxcVU1bUJ3TENLbGNSUEdxZ2lmVFNCanlUanNPeU01STlFazRfOXBlUmN5UmJIZUN6TzdpcXJ4MUJsdWRTenlzeGZScFJfUkRLem8?oc=5", "source_name": "Benzinga", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX - Polaryx Therapeutics Inc Stock Price and Quote", "summary": "Polaryx Therapeutics Inc (PLYX) stock experienced a significant ~28% drop, driven by concerns over cash runway and going concern doubts. The company recently received multiple FDA Fast Track Designations for its SOTERIA basket trial and is actively participating in healthcare con", "url": "https://finviz.com/stock?t=PLYX", "source_name": "Finviz", "published_at": "2026-05-26T20:09:23", "published_display": "26 May 2026 20:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$PLYX stock is down 32% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQcXJVV2Q1MlByMmJDNWlPS00yTVBzV1BDRkJVczBrcHZsOHdaLTVoSzJzSXFocXRTN1dpdUlQOWNLNGRhZ2dZQWJ5WXpFNXBLQW1nRkd0aFRmdlBuZTJscVNVMjhiNm96clY1aE9KQkRhNjZXeVoxNl9KdnlJSElKaUk0UnVQRHRYaUxiNjlqdVdvRk1KcFhsZWs0UEFrcWtjcHhZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies", "summary": "Polaryx Therapeutics, Inc. reported a Q1 2026 net loss of $2.5 million and an accumulated deficit of $102.2 million, with only $250,000 in cash. The company faces significant financial risks, including a \"going concern\" warning due to recurring losses and limited cash, necessitat", "url": "https://www.minichart.com.sg/2026/05/15/polaryx-therapeutics-inc-q1-2026-financial-results-and-pipeline-update-progress-in-rare-pediatric-lysosomal-storage-disorder-therapies/", "source_name": "Minichart", "published_at": "2026-05-15T21:40:57", "published_display": "15 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Receives GHP Magazine\u2019s Healthcare & Pharmaceuticals Awards", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polaryx-therapeutics-receives-ghp-magazine-131500539.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T13:15:00+00:00", "published_display": "14 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX Stock Price and Chart \u2014 NASDAQ:PLYX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5yb04xdnV1NWxCcUt5OFJ2Q1NwSnc0NFVIOFNxQW1oZU16a2FqQUxOU2ZtMkFtbGY2ajhLYmNSM0lRcDdGQm56eVV3RUhBbXF1X0pRcUNJSUdpcjVY?oc=5", "source_name": "TradingView", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics Stock Surges With New Phase Trial Decision\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNVGxvMlV0OWUzSzMxQk91QmtvWUZEbXJqQXVQZ3NNUEFjNmxXd2xHeEpkVkhudFBtaEhwSWdibWRha3JSMGJXR2RXUUU4bHUxTXVmajFtRGlIc29VT2daRThhRjh3M215RG5tSFV3YTRybmY0N3lpNkROTXY2RmUweA?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNTTA3aWNkN0VsX3pQS2c5NWQ3WlBTak1zaHlPZTkyV08xLUtxYUhSQ1dzdmVZWHR6RFVzN2paSkl4ZDZYeWZkRHFLSEtmUWdBVUxJdmZDQUlGeGU1OUlLNl8yNkVNbTdIV2diVXl0Vk42OF9iSGpOU19BSGg0RDdOSzl4bkJGM0NNbmtnVVAwWXlFVC0yUmV0MmJ0OVVZV08wczFXYThqZG1lbWdNUUh4amFreERBeDBFR29kMkN2dlNjYTNOaUROQVAzZFNIUUwwTEJ6TVg0WS03azA5cFNUVmdnaWlIb3F0X3hHeGdxTmdsOEk?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNnRBTFd6S0llSFhnNVZ5VWlUSHRFZE04RlVaS3FyYmEzejFrX3FxSEZTUUgxLWRHaTNiYVFkaU40V0UwbDVueFdwakoxVWg0NGhhMUgxTGtkSG9qTy1qUmhrSzQtZw?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-21T05:31:39+00:00", "published_display": "21 Feb 2026 05:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYOWx4Tkw2N3pIbWdZTFR3d0ZQb3NNT1RVSDFuRDBxZU9PNzFBTEgwbnFOejl5X0R1NF9sc2FhSm9jYWRpNk1peEtfd1FUa240czJsaVBNRmdHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-21T02:28:09+00:00", "published_display": "21 Feb 2026 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE9MWl83QmxVZllZei1OaVFyMWtVNUNBcDdid081TWVjdy1KVnkxaGpaTTBzcmI0Vm9yeUlDaW5veW5VTUYzTU1icHp5R3dEcjY2?oc=5", "source_name": "CNN", "published_at": "2026-02-01T05:58:29+00:00", "published_display": "01 Feb 2026 05:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 80, "total_relevant": 59, "sentiment_summary": {"positive": 19, "negative": 6, "neutral": 34, "score": 56, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "liquidity", "label": "Balance sheet", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 19, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 2.28, "latest_week": "2026-07-17", "one_week_move": -2.1, "four_week_move": -1.7, "twelve_week_move": -53.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -44.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.7479, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.1% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 4}, {"label": "MarketBeat", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Bitget", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 18}, {"label": "Balance sheet", "count": 6}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.1% over one week, -1.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Polaryx Therapeutics Announces Chief Medical Officer Resignation"}], "updated_at": "2026-07-23T05:47:23.032438+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}